SecBot SecBot
PRESS-RELEASE ·Filed Mar 25, 2026

CELC

Celcuity Inc.
MIXED
Impact 8/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The strong clinical data and FDA Priority Review support potential approval and commercialization upside in 2026, but near-term financials reflect heavy pre-launch investment. Traders should monitor topline results from the PIK3CA mutant cohort expected in Q2 2026 and any updates on commercial readiness.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$114.81
T+0 close · Mar 25, 2026 · via day close
Latest settled
−21.55%
T+60 · $90.07
Vs SPY
−35.50%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $114.81entry
  2. T+1 · 8mo ago −7.66%α −5.98% · $106.02
  3. T+5 · 8mo ago −1.90%α −3.53% · $112.63
  4. T+20 · 7mo ago +5.42%α −5.25% · $121.03
  5. T+60 · 5mo ago −21.55%α −35.50% · $90.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celcuity announced strong clinical results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial, with gedatolisib showing a median PFS of 16.6 months versus 1.9 months for fulvestrant, alongside FDA acceptance of its NDA with Priority Review and a PDUFA date of July 17, 2026. However, the company reported a widening net loss of $177.0 million in 2025 compared to $111.8 million in 2024, driven by higher R&D and G&A expenses ahead of a potential 2026 launch.

Key Financial Metrics

Adj. EPS
$-3.22
GAAP: $-3.79

Key Facts

  • FDA accepted NDA for gedatolisib with Priority Review; PDUFA date set for July 17, 2026
  • Phase 3 VIKTORIA-1 trial in PIK3CA WT HR+/HER2- ABC showed median PFS of 16.6 months vs 1.9 months (HR=0.14)
  • Median time to definitive deterioration in well-being was 23.7 months vs 4.0 months (HR=0.39)
  • Full-year 2025 net loss was $177.0 million ($3.79/share), up from $111.8 million ($2.83/share) in 2024
  • R&D expenses rose to $145.0 million in 2025 from $104.2 million in 2024, driven by commercial prep and trial activities
  • Cash, cash equivalents, and short-term investments totaled $441.5 million at year-end, sufficient to fund operations through 2027

Financial Impact

Increased operating expenses led to a 58% YoY increase in net loss, but cash runway extends to 2027

net lossR&D expenseG&A expensecash runway

Risk Factors

  • Topline results from the PIK3CA mutant cohort in Q2 2026 may not replicate the wild-type cohort's success
  • High operating losses and stock-based compensation could pressure sentiment if cash burn accelerates
  • Regulatory risk that FDA may not approve gedatolisib despite Priority Review

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262558

Track record

26 reports on CELC

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +26.84% at T+20 after the Jun 11, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $62.58 Now $60.57 −3.21% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $64.37 Now $60.57 −5.90% settles Nov 23
  3. Nov 9, 20267d ago Press Release Bullish 5/10 Entry $70.37 to $60.57 Now $60.57 −13.93% ▼ −13.93% −12.23% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $66.79 to $64.37 Now $60.57 −9.31% ▼ −3.62% −6.22% vs SPY
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $69.72 to $67.05 Now $60.57 −13.12% ▼ −3.83% −3.24% vs SPY
  7. Oct 24, 202623d ago Press Release Bullish 6/10 Entry $65.80 to $69.13 Now $60.57 −7.95% ▲ +5.06% +6.32% vs SPY
  8. Oct 5, 20266w ago 3 Neutral 2/10 Entry $71.25 to $63.19 Now $60.57 −14.99% ▼ −11.31% −11.17% vs SPY
  9. Oct 2, 20266w ago 8-K Neutral 2/10 Entry $72.10 to $67.94 Now $60.57 −15.99% ▼ −5.77% −6.93% vs SPY
  10. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $79.52 to $65.78 Now $60.57 −23.83% ▼ −17.28% −19.19% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026